Medicine use of interleukin-22

A technology of interleukin and its application, applied in the field of medical application of interleukin-22

Active Publication Date: 2008-07-16
亿一生物制药(北京)有限公司
View PDF19 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no reports on the application of recombinant proteins in reducing blood lipids, diabetes and obesity related to hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine use of interleukin-22
  • Medicine use of interleukin-22
  • Medicine use of interleukin-22

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1 human and mouse interleukin-22 gene cloning

[0072] Cloning of human interleukin-22 gene: Take normal human peripheral blood mononuclear cells and use anti-CD 3 mAb stimulation and incubation overnight. The method of extracting tRNA was ultracentrifugation. cDNA was synthesized by using dT as a primer. Primers for human interleukin-22 gene include sense strand (5'-GCAGAATCTGAACAGGTTC-3') and antisense strand (5'-GGCATCTAATTGTTATTTTCTAG-3') for PCR amplification. The amplified DNA of human interleukin-22 was cloned into the expression vector of Escherichia coli.

[0073] Cloning of mouse interleukin-22 gene: C57BL / 6 female mice were injected with LPS (5 mg / kg, sc), and the spleen was taken 20 hours later to extract RNA. cDNA was synthesized by using dT primer. The primers for mouse interleukin-22 include sense strand (5'-CTCTCACTTATCAACTGTTGAC-3') and antisense strand primers (5'-GATGATGGACGTTAGCTTCTCAC-3'), which are cloned into the Escherichia coli e...

Embodiment 2

[0075] Example 2 Expression of human and mouse interleukin-22 proteins

[0076] Escherichia coli BL21 (E.Coli) was used to express the recombinant protein. E. coli were destroyed with a homogenate under high pressure. Inclusion bodies containing interleukin-22 were obtained by centrifugation. The inclusion bodies were fully washed in a buffer solution (containing 50 mM Tris-HCl pH 8.0, NaCl 100 mM, EDTA 1 mM, DTT 1 mM, Sodium Deoxycholate 0.5%). Inclusion bodies were further dissolved in 8M urea, 50 mM Mes, 10 mM EDTA and 0.1 mM DTT, pH 6.5. The dissolved inclusion bodies were reduced and reset four times in 20 hours in 100mM Tris HCL, 2mM EDTA, 0.5m L-arginine, 1mM reduced glutathione, 0.1mM oxidized glutathione, pH8.0. It was then concentrated and further purified by column chromatography on Superdex75 (Amersham). The recombined protein was eluted with Tris-HCl 20mM, NaCl 50mM pH 7.0. The purity of interleukin-22 was stained with SD3-PAGE gel (purity>95%). And quantita...

Embodiment 3

[0077] Example 3 Recombinant interleukin-22 reduces serum total triglyceride (TG) levels in normal mice

[0078] Normal mice: C56BL / 6, female, 8-12 weeks old, weighing 20-25 grams (n=10). Recombinant mouse interleukin-22 protein was injected subcutaneously every day, the concentration range: 0, 3, 30, 100, 300ug / kg / d. Interleukin-22 was dissolved in 0.1% BSA, Bovine Serum Albumin, PBS, Phosphate Buffered Saline, pH7.0, and injected once a day for 7 consecutive days. The control group was injected with the same volume of solvent: 0.1% BSA, Bovine Serum Albumin, PBS, Phosphate Buffered Saline, pH7.0.

[0079] 100ul of blood was taken from the eye socket at different times after the drug treatment, the blood was allowed to coagulate, the serum was taken and diluted with normal saline, and the content of total triglyceride was measured on an automatic biochemical analyzer.

[0080] The results showed that recombinant mouse interleukin-22 could significantly reduce the concentrat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the medical application of Interleukin-22, in particular to the application of Interleukin-22 for treating hyperlipidemia, hypertriglyceridemia and obesity and (or) diabetes. The invention also relates to the use of preparing medicines for treating hyperlipidemia, hypertriglyceridemia and obesity and (or) diabetes. The Interleukin-22 of the invention is human Interleukin-22, recombination human Interleukin-22, rat Interleukin-22 and (or) recombination rat Interleukin-22.

Description

[0001] This case is a divisional application of the application dated January 4, 2005, the application number is 200510023103.0, and the invention name is "medicine use of interleukin-22". technical field [0002] The present invention relates to the medical use of interleukin-22 (Interleukin-22). It specifically relates to the use of interleukin-22 in the preparation of medicines for treating hyperlipidemia, hypertriglyceridemia, obesity and diabetes. Background technique [0003] Metabolic diseases include obesity, diabetes, hyperlipoproteinemia, hyperglycemia, hyperinsulinemia, etc., which seriously affect human health. The pathogenesis of these diseases is not yet fully understood, but it is generally believed that genetic factors, environmental factors and human living habits lead to the occurrence of these diseases. [0004] Obesity (Obesity) is a social chronic disease, which means that the intake of calories in the body is greater than the consumption, resulting in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61P3/06A61P3/10A61P3/04
Inventor 陈旭文黄予良
Owner 亿一生物制药(北京)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap